Lantheus falls after report it is considering potential $7 billion sale
22/05/2026 23:27
** Shares of radiopharmaceutical-focused company Lantheus Holdings LNTH.O fall 2% to $101 in extended trading ** LNTH is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reports ** The cos have been in discussions about a potential deal that could be weeks away, the report says, citing people familiar with the matter ** Lantheus declined to comment ** The reports adds that no final decision has been made and the talks may not result in a transaction ** As of last close, stock up 54.8% YTD (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))
Recent news on Lantheus Holdings
See all newsBrief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale